SPRC vs. EVFM, EVLO, SBFM, BLPH, HSTO, CMRA, SXTC, APVO, ADTX, and GRI
Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Evofem Biosciences (EVFM), Evelo Biosciences (EVLO), Sunshine Biopharma (SBFM), Bellerophon Therapeutics (BLPH), Histogen (HSTO), Comera Life Sciences (CMRA), China SXT Pharmaceuticals (SXTC), Aptevo Therapeutics (APVO), Aditxt (ADTX), and GRI Bio (GRI). These companies are all part of the "pharmaceutical preparations" industry.
Evofem Biosciences (NASDAQ:EVFM) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
In the previous week, SciSparc had 2 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for SciSparc and 0 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 1.44 beat SciSparc's score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.
Evofem Biosciences has a net margin of 290.81% compared to Evofem Biosciences' net margin of 0.00%. Evofem Biosciences' return on equity of 0.00% beat SciSparc's return on equity.
0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Evofem Biosciences received 260 more outperform votes than SciSparc when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 66.67% of users gave SciSparc an outperform vote.
Evofem Biosciences has higher revenue and earnings than SciSparc.
Evofem Biosciences has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Summary
SciSparc beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.
Get SciSparc News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SciSparc Competitors List
Related Companies and Tools
